van den Broek LA - Search Results

1

Glucosidase trimming inhibitors preferentially perturb T cell activation induced by CD2 mAb.

van Kemenade FJ, Rotteveel FT, van den Broek LA, Baars PA, van Lier RA, Miedema F. van Kemenade FJ, et al. Among authors: van lier ra, van den broek la. J Leukoc Biol. 1994 Aug;56(2):159-65. doi: 10.1002/jlb.56.2.159. J Leukoc Biol. 1994. PMID: 7915296

2

Synthesis of alpha-glucosidase I inhibitors showing antiviral (HIV-1) and immunosuppressive activity.

van den Broek LA, Kat-Van Den Nieuwenhof MW, Butters TD, Van Boeckel CA. van den Broek LA, et al. Among authors: van boeckel ca. J Pharm Pharmacol. 1996 Feb;48(2):172-8. doi: 10.1111/j.2042-7158.1996.tb07117.x. J Pharm Pharmacol. 1996. PMID: 8935166

3

Lipophilic analogues of sparsomycin as strong inhibitors of protein synthesis and tumor growth: a structure-activity relationship study.

van den Broek LA, Lázaro E, Zylicz Z, Fennis PJ, Missler FA, Lelieveld P, Garzotto M, Wagener DJ, Ballesta JP, Ottenheijm HC. van den Broek LA, et al. J Med Chem. 1989 Aug;32(8):2002-15. doi: 10.1021/jm00128a051. J Med Chem. 1989. PMID: 2754719

4

The N-benzyl derivative of the glucosidase inhibitor 1-deoxynojirimycin shows a prolonged half-life and a more complete oral absorption in the rat compared with the N-methyl analog.

Faber ED, van den Broek LA, Oosterhuis EE, Stok BP, Meijer DK. Faber ED, et al. Among authors: van den broek la. Drug Deliv. 1998;5(1):3-12. doi: 10.3109/10717549809052021. Drug Deliv. 1998. PMID: 19570011

5

The development of sparsomycin as an anti-tumour drug.

Ottenheijm HC, van den Broek LA. Ottenheijm HC, et al. Among authors: van den broek la. Anticancer Drug Des. 1988 Mar;2(4):333-7. Anticancer Drug Des. 1988. PMID: 3365303

6

Correlation of the in vitro cytotoxicity of ethyldeshydroxysparsomycin and cisplatin with the in vivo antitumour activity in murine L1210 leukaemia and two resistant L1210 subclones.

Hofs HP, Wagener DJ, de Valk-Bakker V, van Rennes H, van Zeist AJ, van den Broek LA, Ottenheijm HC. Hofs HP, et al. Among authors: van rennes h, van zeist aj, van den broek la. Cancer Chemother Pharmacol. 1993;31(4):289-94. doi: 10.1007/BF00685673. Cancer Chemother Pharmacol. 1993. PMID: 8422692

7

Pharmacokinetics and toxicology of sparsomycin in beagle dogs.

Zylicz Z, Wagener DJ, Fernandez del Moral P, van Rennes H, Wessels JM, Winograd B, van der Kleijn E, Vree TB, van Haelst U, van den Broek LA, et al. Zylicz Z, et al. Among authors: van rennes h, van der kleijn e, van den broek la, van haelst u. Cancer Chemother Pharmacol. 1987;20(2):115-24. doi: 10.1007/BF00253964. Cancer Chemother Pharmacol. 1987. PMID: 3664930

8

Potentiation of cisplatin antitumour activity by Ethyldeshydroxy-Sparsomycin in L1210 leukemia.

Hofs HP, Wagener DJ, De Valk-Bakker V, Van Rennes H, Van Zeist AJ, Van Den Broek LA, Ottenheijm HC. Hofs HP, et al. Among authors: van rennes h, van zeist aj, van den broek la. Anticancer Res. 1992 Jan-Feb;12(1):167-70. Anticancer Res. 1992. PMID: 1567164

9

Pharmacokinetics of the antitumor antibiotic n-pentyl-sparsomycin in beagle dogs.

Zylicz Z, Wagener DJ, Garzotto M, Vree TB, van der Kleijn E, van den Broek LA, Ottenheijm HC. Zylicz Z, et al. Among authors: van der kleijn e, van den broek la. Invest New Drugs. 1990 Feb;8(1):25-32. doi: 10.1007/BF00216921. Invest New Drugs. 1990. PMID: 2345068

10

Modulation of the in vitro cytotoxicity of seven anticancer drugs by protein synthesis inhibition using sparsomycin.

Zylicz Z, Hofs HP, Wagener DJ, Van Rennes H, Wessels JM, van den Broek LA, Ottenheijm HC. Zylicz Z, et al. Among authors: van rennes h, van den broek la. Anticancer Res. 1989 Nov-Dec;9(6):1835-40. Anticancer Res. 1989. PMID: 2483308

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

74 results

Search Page